Business
Co-devlopment Agreement
Co-devlopment Agreement.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n Co-devlopment Agreement22 April 2013 SAREUM HOLDINGS PLC and SRI INTERNATIONAL(\"SAREUM\" and \"SRI\")SAREUM and SRI INTERNATIONAL ANNOUNCE AGREEMENT to ADVANCE DEVELOPMENT of TYROSINE KINASE 2 INHIBITORS for TREATMENT of AUTOIMMUNE and INFLAMMATORY DISEASESCambridge, UK and Menlo Park, Calif. - April 22 2013 - Sareum (AIM: SAR), the specialist cancer drug discovery business, has entered a co-development agreement with independent nonprofit research and development institute SRI International to advance Sareum's Tyrosine Kinase 2 (TYK2) small molecule drug discovery program for readiness in human clinical trials.Under the agreement, research will focus on the discovery and development of small molecule therapeutics targeting TYK2, one of the four janus kinase (JAK) family members implicated in a number of inflammatory diseases.Sareum's CEO, Dr. Tim Mitchell, commented, \"The agreement with SRI gives us access to world-class autoimmune disease biology and drug development expertise. It validates both our business model and the quality of our own research. We are delighted to be working with SRI. As we have stated in the past, our intention has been to enter into agreements that help develop our research into commercially viable products in the most effective and efficient way.\" As part of the agreement, SRI Biosciences' Center for Immunology and Infectious Diseases will co-lead discovery and development activities. Sareum will retain the option to further develop and commercialize the program. \"Because of TYK2's critical role in the signalling of inflammatory cytokines, there is strong scientific rationale for developing TYK2 inhibitors for the treatment of autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, sepsis, and Crohn's Disease,\" said Annalisa D'Andrea, Ph.D., senior director of SRI's Center for Immunology and Infectious Diseases. \"Combining SRI's expertise in autoimmune and inflammatory diseases with Sareum's experience in compound design will enable us to develop much-needed products that may benefit people throughout the world.\" For further information:Sareum Holdings plcTim Mitchell01223 497 700Sanlam Securities UK (Nomad)Simon Clements020 7628 2200Hybridan LLP (Broker)Claire Noyce / Deepak Reddy020 7947 4350The Communications Portfolio (Media enquiries)Ariane ComstiveA...